Molecular Partners

Sole Block Placing Agent

Van Lanschot Kempen is pleased to announce that it acted as a Sole Block Placing Agent in the placement of 1.3m Molecular Partners shares

Transaction highlights

Van Lanschot Kempen crossed 1.3 million Molecular Partners shares, representing a c. 4.0% of the outstanding share capital
The transaction builds on the long-standing relationship between Molecular Partners and Van Lanschot Kempen including its involvement in a block trade of c. 4% of the company’s shares in January 2022, the Nasdaq IPO in 2021, the Accelerated Bookbuild Offering in 2020, and the block trade of c. 5% of the company’s shares in 2019
This smoothly executed block trade demonstrates another avenue where Van Lanschot Kempen provides added value to the European life sciences universe and can assist investors by leveraging its strong international investor network to find the right counterparties

Company description

Molecular Partners is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

Van Lanschot Kempen Life Sciences & Healthcare credentials

Sole Financial Adviser to Gensight Biologics securing a €35 million credit facility from the European Investment Bank
Joint Global Coordinator and Joint Bookrunner in Xbrane’s SEK 170 million Capital Increase
Co-Lead Manager in Zealand Pharma’s DKK 786 million Capital Increase
Sole Financial Adviser in Mendus’ up to SEK 250 million of financing commitments
Sole Financial Adviser in the sale of Sanquin Reagents by Sanquin Health Solutions to Gilde Healthcare
Joint Global Coordinator in BioInvent’s SEK 299 million directed share issue
Sole Global Coordinator Abliva’s SEK 200 million financing consisting of a SEK 150m PIPE and a SEK 50m Fully Guaranteed Rights Issue
Joint Global Coordinator & Joint Bookrunner in SynAct Pharma’s SEK 150 million Fully Guaranteed Rights Issue
Co-Manager in the USD 700 million Capital Increase by argenx
Sole Block Placing Agent in the placement of 1.4m Molecular Partners shares
Joint Bookrunner in the USD 127 million Nasdaq IPO of Forbion European Acquisition Corp
Co-Lead Manager in the USD 115 million Nasdaq IPO by IO Biotech

Curious to know more?

Jan de Kerpel

Mail Jan de Kerpel